Pharmaceutical compound
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.149.406 |
Chemical and physical data | |
Formula | C24H25FN6O |
Molar mass | 432.503 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Mizolastine (Mizollen) is a once-daily, non-sedating antihistamine. It blocks H1 receptors and is commonly fast-acting. It does not prevent the actual release of histamine from mast cells, it only prevents histamine from binding to receptors. Side effects can include dry mouth and throat.
References
- Simons FE (March 1999). "Mizolastine: antihistaminic activity from preclinical data to clinical evaluation". Clinical and Experimental Allergy. 29 (Suppl 1): 3–8. doi:10.1046/j.1365-2222.1999.00002.x. PMID 10209699. S2CID 616333.
- "MIZOLASTINE: British National Formulary". Retrieved 2010-02-01.
Antihistamines (R06) | |
---|---|
Benzimidazoles (*) | |
Diarylmethanes |
|
Ethylenediamines | |
Tricyclics |
|
Others |
|
For topical use |
This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it. |